Your browser doesn't support javascript.
loading
Immune response to allogeneic equine mesenchymal stromal cells.
Kamm, J Lacy; Riley, Christopher B; Parlane, Natalie A; Gee, Erica K; McIlwraith, C Wayne.
Afiliación
  • Kamm JL; School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand. lacykamm@gmail.com.
  • Riley CB; School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand.
  • Parlane NA; AgResearch, Hopkirk Research Institute, Massey University, Palmerston North, 4474, New Zealand.
  • Gee EK; School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand.
  • McIlwraith CW; School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand.
Stem Cell Res Ther ; 12(1): 570, 2021 11 12.
Article en En | MEDLINE | ID: mdl-34772445
BACKGROUND: Mesenchymal stromal cells (MSCs) are believed to be hypoimmunogeneic with potential use for allogeneic administration. METHODS: Bone marrow was harvested from Connemara (n = 1), Standardbred (n = 6), and Thoroughbred (n = 3) horses. MSCs were grouped by their level of expression of major histocompatibility factor II (MHC II). MSCs were then sub-grouped by those MSCs derived from universal blood donor horses. MSCs were isolated and cultured using media containing fetal bovine serum until adequate numbers were acquired. The MSCs were cultured in xenogen-free media for 48 h prior to use and during all assays. Autologous and allogeneic MSCs were then directly co-cultured with responder leukocytes from the Connemara horse in varying concentrations of MSCs to leukocytes (1:1, 1:10, and 1:100). MSCs were also cultured with complement present and heat-inactivated complement to determine whether complement alone would decrease MSC viability. MSCs underwent haplotyping of their equine leukocyte antigen (ELA) to determine whether the MHC factors were matched or mismatched between the donor MSCs and the responder leukocytes. RESULTS: All allogeneic MSCs were found to be ELA mismatched with the responder leukocytes. MHC II-low and universal blood donor MSCs caused no peripheral blood mononuclear cell (PBMC) proliferation, no increase in B cells, and no activation of CD8 lymphocytes. Universal blood donor MSCs stimulated a significant increase in the number of T regulatory cells. Neutrophil interaction with MSCs showed that universal blood donor and MHC II-high allogeneic MSCs at the 6 h time point in co-culture caused greater neutrophil activation than the other co-culture groups. Complement-mediated cytotoxicity did not consistently cause MSC death in cultures with active complement as compared to those with inactivated complement. Gene expression assays revealed that the universal blood donor group and the MHC II-low MSCs were more metabolically active both in the anabolic and catabolic gene categories when cultured with allogeneic lymphocytes as compared to the other co-cultures. These upregulated genes included CD59, FGF-2, HGF, IDO, IL-10, IL-RA, IL-2, SOX2, TGF-ß1, ADAMSTS-4, ADAMSTS-5, CCL2, CXCLB/IL-8, IFNγ, IL-1ß, and TNFα. CONCLUSIONS: MHC II-low MSCs are the most appropriate type of allogeneic MSC to prevent activation of the innate and cell-mediated component of the adaptive immune systems and have increased gene expression as compared to other allogeneic MSCs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Células Madre Mesenquimatosas Límite: Animals Idioma: En Revista: Stem Cell Res Ther Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Células Madre Mesenquimatosas Límite: Animals Idioma: En Revista: Stem Cell Res Ther Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Reino Unido